New studies on retatrutide, a dual activator for glucagon-like peptide-1 and gastric inhibitory polypeptide, indicate significant findings in addressing weight gain and type 2 glucose intolerance. Early evidence from clinical experiments show notable reductions in body bulk and enhanced glucose r